Trials / Unknown
UnknownNCT05440045
A Clinical Study of 6MW3211 in Patients With Renal Cancer
A Phase 2, Multicenter, Open-Label Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Advanced Clear Cell Renal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
Detailed description
This study is a single arm, non-randomized, multicenter, open label, phase 2 clinical trial to evaluate preliminary efficacy and safety in patients with advanced clear cell renal cacer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 6MW3211 | 6MW3211 injection, 30mg/kg, Q2W |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-01-01
- Completion
- 2024-09-01
- First posted
- 2022-06-30
- Last updated
- 2022-08-17
Source: ClinicalTrials.gov record NCT05440045. Inclusion in this directory is not an endorsement.